Bratislavské lekárske listy/Bratislava medical journal · 2016 · 13 citations · 10 references
MedicineImmunologyPharmacologyApoptosisGene ExpressionInflammationChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease PharmacotherapyNeuroprotectionObstructive Lung DiseasePulmonary InflammationPulmonary ToxicityBiomarkers Of Pulmonary InjuryControl Group DesignDexmedetomidine AnalgesiaDexmedetomidine PharmacologyLung Function DeclineLung Function TestingLung ProtectionMatched Control Group
OBJECTIVE: To study the mechanism of protection provided by dexmedetomidine against COPD-induced lung injury. METHODS: COPD rat model was determined by measuring lung function, and comparing HE staining between two different groups. We got the lung tissue and cells from the control and COPD groups. The cells were divided into three groups: control group, and blank and drug groups that were from the COPD rats. Cell apoptosis, relative gene expression and TNF-α and IL-1β from nutrient solution were measured. RESULTS: The TV, PEF, EF50, FEV0.3 and FEV0.3/FVC in COPD group were significantly lower than in control group (1.26±0.17 vs 2.65±0.21; 17.61±0.35 vs 38.55±0.24; 1.20±0.14 vs 1.81±0.06; 2.52±0.28 vs 4.44±0.26; 63.39±0.22 vs 88.45±0.34, p < 0.05, respectively). Cell apoptosis was significantly different in blank and drug groups (21.65±0.86 vs 10.74±0.15; p < 0.05, respectively). The gene expressions of miRNA-146a, p53 and Bcl-2 were significantly downregulated compared with blank group. CONCLUSION: Dexmedetomidine protected COPD-induced lung injury by inhibiting miRNA-146a expression to reduce cell apoptosis (Tab. 1, Fig. 3, Ref. 25).
10
Konstantin D. Taganov, Mark Boldin, Kuang‐Jung Chang et al. · Proceedings of the National Academy of Sciences · 2006 · 4.3K citations · Full text
Pratik P. Pandharipande, Robert D. Sanders, Timothy D. Girard et al. · Critical Care · 2010 · 418 citations · Full text